Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP 36 14-Day RSI is 40.52 as of Jul. 30, 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 2,114 Consumer Packaged Goods companies, Integrated Biopharma ranks better than 77.06% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Integrated Biopharma 14-Day RSI Related Terms
INBP vs HCWC, PAVS, BABB: 14-Day RSI Comparison
For the Packaged Foods subindustry, Integrated Biopharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma 14-Day RSI vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma (INBP) has a 14-Day RSI of 40.52 as of Jul. 30, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Integrated Biopharma and its competitors. According to the industry distribution chart, Integrated Biopharma ranks #485 out of 2114 companies in the Consumer Packaged Goods industry, placing it in the top 22.9%.
Is Integrated Biopharma's 14-Day RSI too high?
Integrated Biopharma's current 14-Day RSI is 40.52. The Consumer Packaged Goods industry median 14-Day RSI is 49.32. Integrated Biopharma's value of 40.52 is 17.8% below this industry median. Based on the distribution chart, Integrated Biopharma ranks #485 out of 2114 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's 14-Day RSI compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #485 out of 2114 companies for 14-Day RSI. This places Integrated Biopharma in the top 23% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 49.32. Integrated Biopharma's value of 40.52 is 17.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Consumer Packaged Goods company?
The median 14-Day RSI among Consumer Packaged Goods companies is 49.32, based on 2,114 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Biopharma's current 14-Day RSI of 40.52 is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Integrated Biopharma and its competitors. For the Consumer Packaged Goods industry, the median 14-Day RSI is 49.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current 14-Day RSI is 40.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current 14-Day RSI is 40.52 and 17.8% below the Consumer Packaged Goods industry median of 49.32. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current 14-Day RSI is 40.52 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
14-Day RSI: 40.52
GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
Industry Position: 17.8% below the Consumer Packaged Goods median (#485 of 2114)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
